AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support. It also offers thrombolytic catheters to deliver thrombolytic agents; angiographic products and accessories for use in during peripheral vascular interventional procedures; drainage products, which drain abscesses and other fluid pockets; and micro access sets. In addition, the company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; and Asclera injection for treating uncomplicated spider and reticular veins of the lower extremities. Further, it provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation system; and radiofrequency ablation products for ablating solid cancerous or benign tumors. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone518-795-1400
Debt
Current Ratio2.88
Quick Ratio1.86
Price-To-Earnings
Sales & Book Value
Annual Sales$344.29 million
Price / Sales2.24
Price / Cash Flow14.70
Price / Book1.40
Profitability
Net Income$16.33 million
Net Margins5.10%
Return on Assets4.41%
Miscellaneous
Employees1,145
OptionableOptionable
AngioDynamics (NASDAQ:ANGO) Frequently Asked Questions
What is AngioDynamics' stock symbol?
AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."
How were AngioDynamics' earnings last quarter?
AngioDynamics, Inc. (NASDAQ:ANGO) posted its earnings results on Friday, January, 4th. The medical instruments supplier reported $0.22 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.21 by $0.01. The medical instruments supplier had revenue of $91.50 million for the quarter, compared to analyst estimates of $89.24 million. AngioDynamics had a return on equity of 5.85% and a net margin of 5.10%. The company's revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter last year, the company earned $0.16 earnings per share. View AngioDynamics' Earnings History.
When is AngioDynamics' next earnings date?
What guidance has AngioDynamics issued on next quarter's earnings?
AngioDynamics updated its FY19 earnings guidance on Friday, January, 4th. The company provided EPS guidance of $0.82-0.86 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.84. The company issued revenue guidance of $354-359 million, compared to the consensus revenue estimate of $356.09 million.AngioDynamics also updated its FY 2019 guidance to $0.82-0.86 EPS.
What price target have analysts set for ANGO?
3 Wall Street analysts have issued 1-year price objectives for AngioDynamics' shares. Their predictions range from $16.33 to $23.00. On average, they expect AngioDynamics' share price to reach $19.6650 in the next year. This suggests that the stock has a possible downside of 5.4%. View Analyst Price Targets for AngioDynamics.
What is the consensus analysts' recommendation for AngioDynamics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AngioDynamics.
Has AngioDynamics been receiving favorable news coverage?
Media headlines about ANGO stock have trended positive on Thursday, InfoTrie reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. AngioDynamics earned a news sentiment score of 2.3 on InfoTrie's scale. They also assigned media headlines about the medical instruments supplier a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the stock's share price in the immediate future.
Who are some of AngioDynamics' key competitors?
Some companies that are related to AngioDynamics include Merit Medical Systems (MMSI), Tandem Diabetes Care (TNDM), NuVasive (NUVA), Glaukos (GKOS), Irhythm Technologies (IRTC), Mazor Robotics (MZOR), Atrion (ATRI), K2M Group (KTWO), Nevro (NVRO), AtriCure (ATRC), Tactile Systems Technology (TCMD), Luminex (LMNX), Cryolife (CRY), Cardiovascular Systems (CSII) and Orthofix Medical (OFIX).
Who are AngioDynamics' key executives?
AngioDynamics' management team includes the folowing people:
- Mr. James C. Clemmer, CEO, Pres & Director (Age 55)
- Mr. Michael C. Greiner, Exec. VP & CFO (Age 46)
- Mr. David D. Helsel, Sr. VP of Global Operations and R&D (Age 55)
- Mr. Stephen A. Trowbridge, Sr. VP & Gen. Counsel (Age 45)
- Mr. Robert A. Simpson, Sr. VP & GM of Vascular Interventions and Therapies (Age 47)
Who are AngioDynamics' major shareholders?
AngioDynamics' stock is owned by many different of institutional and retail investors. Top institutional investors include Boston Advisors LLC (0.13%) and Louisiana State Employees Retirement System (0.04%). Company insiders that own AngioDynamics stock include Avista Capital Partners Gp, Ll, James C Clemmer, Jan Stern Reed and Michael Greiner. View Institutional Ownership Trends for AngioDynamics.
Which major investors are selling AngioDynamics stock?
Which major investors are buying AngioDynamics stock?
ANGO stock was purchased by a variety of institutional investors in the last quarter, including Boston Advisors LLC. Company insiders that have bought AngioDynamics stock in the last two years include James C Clemmer and Jan Stern Reed. View Insider Buying and Selling for AngioDynamics.
How do I buy shares of AngioDynamics?
Shares of ANGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AngioDynamics' stock price today?
One share of ANGO stock can currently be purchased for approximately $20.79.
How big of a company is AngioDynamics?
AngioDynamics has a market capitalization of $752.77 million and generates $344.29 million in revenue each year. The medical instruments supplier earns $16.33 million in net income (profit) each year or $0.74 on an earnings per share basis. AngioDynamics employs 1,145 workers across the globe.
What is AngioDynamics' official website?
How can I contact AngioDynamics?
AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier can be reached via phone at 518-795-1400 or via email at [email protected]
MarketBeat Community Rating for AngioDynamics (NASDAQ ANGO)
MarketBeat's community ratings are surveys of what our community members think about AngioDynamics and other stocks. Vote "Outperform" if you believe ANGO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANGO will underperform the S&P 500 over the long term. You may vote once every thirty days.
